Qulipta Generates $398 Million as Revenue Grows 38.2% in Third Quarter
Key Facts
Qulipta generated global revenue of $398 million in the third quarter of 2026, up 38.2% on a reported basis year over year, according to AbbVie’s results released on October 30. Revenue growth was 38.5% on an operational basis, reflecting the exclusion of foreign-exchange effects from the comparison. In the same period, Ubrelvy generated revenue of $449 million, up 26.9% on a reported basis. The results put the two drugs among the company’s migraine portfolio growth drivers during the quarter. The figures followed Qulipta revenue of $350 million in the second quarter, up 30.9% on a reported basis year over year.
The quarterly comparison shows an acceleration in Qulipta’s reported revenue growth, from 30.9% in the second quarter to 38.2% in the third quarter, as revenue increased from $350 million to $398 million. Combined revenue for Ubrelvy and Qulipta was also $742 million in the second quarter, according to company data. Among the other neuroscience treatments cited in the results, Vraylar revenue was about $1.068 billion, up 14.3% from the same period a year earlier. Botox Therapeutic generated revenue of $1.080 billion, up 9.8% on a reported basis year over year. The figures show differing growth rates among the company’s products during the quarter, with the two migraine drugs recording higher growth than the other two products cited.
Diluted earnings per share in the third quarter were $2.37 under generally accepted accounting principles, compared with $3.82 on an adjusted basis, AbbVie said. The company said the results included a negative impact of $0.11 per share from acquired in-process research and development expenses and milestone payments. AbbVie raised its 2026 adjusted earnings-per-share forecast range to $13.95–$13.99, from a previous range of $13.76 to $13.96. The chief executive said the company was raising its forecast and dividend amid strong prospects and momentum. AbbVie also announced an increase in its quarterly cash dividend from $1.73 to $1.82 per share, with the new dividend to begin being paid on February 16, 2027.
In a clinical development related to its migraine portfolio, AbbVie announced positive topline results in September from the Phase 3 LUNA study, which tested atogepant for menstrual-related migraine. The company said the average reduction in migraine days was 1.20 days with treatment, compared with 0.40 days with placebo, a difference of 0.80 days in favor of treatment, with a p-value below 0.0001. It added that the drug met the primary endpoint and all eight ranked secondary endpoints, and that safety results showed no new signals compared with the known safety profile. The study included 468 adult participants at sites in Europe and Asia and was multicenter, randomized, double-blind and placebo-controlled, with an open-label extension. The protocol assessed treatment taken for seven consecutive days starting three days before menstruation, over three menstrual cycles.
AbbVie said there are currently no approved treatments for menstrual-related migraine and that it plans to submit LUNA data to health authorities around the world and present it at future medical conferences. The announced results do not represent a new regulatory approval for this use; the next step announced by the company remains submitting the data and sharing it with the medical community. As background to the study, the company noted that 66% of eligible participants in the CaMEO-I study reported migraine attacks around the time of menstruation. AbbVie quoted a researcher at the University of Pavia as saying that menstrual-related migraine attacks are often more severe and harder to treat. The researcher said LUNA is the first study of a CGRP-targeted treatment to report positive results specifically for this type of migraine.